

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Sanberg, et al.** )  
Serial No.: **09/526,403** )  
Filing Date: **March 15, 2000** )  
For: **METHOD OF TREATING** )  
**COGNITIVE DEFECTS IN** )  
**LEARNING AND MEMORY** )

Examiner: **To be assigned**  
Art Unit: **1617**  
Docket No.: **T103 F1016.1**  
**(formerly LAY-003CID)**

**PRELIMINARY AMENDMENT**

Prior to examination of the above-captioned application, Applicants request that the claims be amended in accordance with the following:

***In the Claims:***

Please amend claims 4 and 12, and add new claims 15-71 as indicated in the attached Complete Listing of the Claims.

**REMARKS**

Claims 1-71 are pending. Original claims 4 and 12 have been amended to correct an obvious typographic error. New claims 15-71 have been added. New claims 15-71 have been added into order to recite embodiments of the invention relating to effective amounts of "mecamylamine, a mecamylamine analog, or a mecamylamine stereoisomer," as well as embodiments relating to administration "in a controlled release dosage form" and "by bronchial inhalation."

New claims 15-41, 43-51, 53-61, and 63-71 find support throughout the specification, e.g., at page 6, line 24 through page 7, line 6; at page 8, line 9; at page 11, line 23 through page 12, line 1 ("sustained or delayed release dosage form"); and at page 13, line 3 ("bronchial